Immunic, Inc. (IMUX)
NASDAQ: IMUX · Real-Time Price · USD
1.210
-0.030 (-2.42%)
Oct 31, 2024, 4:00 PM EDT - Market closed

Company Description

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany.

Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.

The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases.

Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

Immunic, Inc.
Immunic logo
Country United States
Founded 2016
Industry Biotechnology
Sector Healthcare
Employees 77
CEO Daniel Vitt

Contact Details

Address:
1200 Avenue of the Americas, Suite 200
New York, New York 10036
United States
Phone 332 255 9818
Website imux.com

Stock Details

Ticker Symbol IMUX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001280776
CUSIP Number 4525EP101
ISIN Number US4525EP1011
Employer ID 56-2358443
SIC Code 2834

Key Executives

Name Position
Dr. Daniel Vitt Ph.D. Chief Executive Officer and Director
Dr. Duane D. Nash J.D., M.B.A., M.D. Executive Chairman
Glenn Whaley CPA Chief Financial Officer
Dr. Andreas Muehler M.D., Ph.D. Chief Medical Officer
Jason Tardio M.B.A. Chief Operating Officer and President
Dr. Hella Kohlhof Chief Scientific Officer
Jessica Breu Head of Investor Relations and Communications
Inderpal Singh General Counsel
Patrick Walsh Chief Business Officer
Werner Gladdines Chief Development Officer

Latest SEC Filings

Date Type Title
Oct 22, 2024 8-K Current Report
Sep 10, 2024 8-K Current Report
Sep 3, 2024 8-K Current Report
Aug 8, 2024 10-Q Quarterly Report
Aug 8, 2024 8-K Current Report
Jul 24, 2024 8-K Current Report
Jul 9, 2024 8-K Current Report
Jul 2, 2024 S-8 Securities to be offered to employees in employee benefit plans
Jun 13, 2024 8-K Current Report
Jun 10, 2024 424B5 Filing